INO has been the topic of a number of other research reports. JMP Securities initiated coverage on shares of Inovio Pharmaceuticals in a research note on Thursday, January 4th. They set a “market outperform” rating and a $12.00 price objective on the stock. Oppenheimer upgraded shares of Inovio Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $4.00 price target for the company in a research note on Thursday, January 25th.
Inovio Pharmaceuticals Trading Down 1.5 %
Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) last released its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($1.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.56) by $0.48. Inovio Pharmaceuticals had a negative net margin of 19,271.31% and a negative return on equity of 84.52%. The business had revenue of $0.39 million for the quarter, compared to analysts’ expectations of $0.18 million. On average, equities research analysts predict that Inovio Pharmaceuticals will post -5.8 earnings per share for the current year.
Institutional Trading of Inovio Pharmaceuticals
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Graham Capital Management L.P. acquired a new position in Inovio Pharmaceuticals during the first quarter valued at approximately $29,000. Allspring Global Investments Holdings LLC acquired a new position in Inovio Pharmaceuticals during the second quarter valued at approximately $30,000. Mariner LLC grew its holdings in Inovio Pharmaceuticals by 469.0% during the third quarter. Mariner LLC now owns 76,093 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 62,719 shares during the last quarter. ExodusPoint Capital Management LP acquired a new position in Inovio Pharmaceuticals during the second quarter valued at approximately $34,000. Finally, CI Private Wealth LLC acquired a new position in Inovio Pharmaceuticals during the fourth quarter valued at approximately $37,000. Institutional investors and hedge funds own 26.79% of the company’s stock.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
- Five stocks we like better than Inovio Pharmaceuticals
- How to Use the MarketBeat Stock Split Calculator
- 5 best stocks to buy in a bear market
- The 3 Best Retail Stocks to Shop for in August
- 2 REIT stocks set to surge due to red hot data center demand
- How to Invest in Toy Stocks
- How and when to use LEAPS stock options
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.